Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 111

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 111
---
center'>71</div>

LPLT protein delivery technology is patent protected.

Pursuant to the Yissum License Agreements, we
have an exclusive, worldwide license for the development, use, manufacture and commercialization of products arising out of patents owned
by, and patent applications filed by, Yissum in connection with LPLT vaccination approach.

The patent listed below was licensed to us on
an exclusive basis by Yissum pursuant to the Yissum License Agreements.

| Status  |     | Country |     | Application 
 Date        |     | Publication  
 Number       |     | Patent   
 Date     |     |    Patent 
    Number |     | Expiry   
 Date     |
| Granted |     | US      |     | May         
 5, 2006     |     | 2006/0252717 |     | March    
 18, 2014 |     | 8,673,285 |     | February 
 18, 2027 |

The U.S. patent referenced above relate to the
proprietary lipid-based delivery system developed in Prof. Barenholz’s laboratory at the Hebrew University of Jerusalem. This patent,
protects the composition and method of use of a liposomal nanoparticle platform incorporating ceramide carbamoyl spermine (CCS) for the
delivery of recombinant protein antigens in vaccine formulations. They include composition of matter claims and methods of use for prophylactic
and therapeutic immunization.

Planned Patent Applications and Timeline

Our liposomal vaccine platform is designed to
co-encapsulate multiple recombinant protein antigens within a proprietary lipid nanoparticle system incorporating ceramide carbamoyl
spermine (CCS), a synthetic lipid developed to enhance immunogenicity, antigen stability, and mucosal delivery. As mentioned previously,
this platform has been initially evaluated in preclinical models for two viral targets: SARS-CoV-2 and West Nile Virus (WNV). The dual-antigen
design includes the receptor binding domain (RBD) and nucleocapsid (N) proteins for SARS-CoV-2, and the EDIII and NS1 proteins for WNV,
offering both neutralizing antibody and T-cell mediated immune responses.

Assuming the acceptable outcome of the ongoing
long-term challenge animal study and our positive determination as o the commercial viability of the protein-based vaccine, we plan to
submit a new provisional patent application we are covering the co-enc